Gadoteric Acid — Drug Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

4 Recruiting

7 Completed trials

16 Sponsors

13 Countries

Phase III

Phase II

Phase IV

Phase III: 4 Phase II: 5 Phase I/II: 1 Phase III/IV: 1 Phase IV: 3 Phase I (FiH): 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Indications tested

Magnetic resonance imaging 2 Chronic disease 1 Prostate cancer 1 Huntington's disease 1 Coronary artery occlusion 1 Relapsing multiple sclerosis 1

Sponsors using this IMP

Bayer AG 2 Aarhus Universitet 1 AskBio France 1 Assistance Publique Hopitaux De Paris 1 Biogen Idec Research Limited 1 Bracco Imaging S.p.A. 1 Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer 1 Guerbet 1 Hospices Civils De Lyon 1 IC Targets AS 1 Iqvia Rds France 1 Radboud universitair medisch centrum Stichting 1

All trials

15 total

The effect of suprainguinal fascia iliaca compartment block Not authorised

2023-510388-37-00 Phase II 1 country Region Midtjylland
Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY Pending

2024-515462-14-00 Phase IV 3 countries Iqvia Rds France
Evaluation of the efficacy and safety of Magnetic Resonance Angiography (MRA) using gadopiclenol compared to gadoterate meglumine in the ass… Pending

2024-518835-13-00 Phase III 7 countries Bracco Imaging S.p.A.; Guerbet
Evaluation of patients with total coronary occlusions with multimodality image. Pending

2024-519979-26-00 Phase IV 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
Efficacy of Reduced Gadolinium Dose in Contrast-Enhanced Breast MRI Recruiting

2024-518549-27-00 Phase III/IV 1 country Radboud universitair medisch centrum Stichting
Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation Recruiting

2022-501892-14-00 Phase III 1 country Region Vasterbotten; Umea University
HYPER-trial Hyperemic mYocardial Perfusion by adEnosine at diffeRent doses Recruiting

2023-505248-20-00 Phase IV 1 country Region Skane
IMPROCAS - Improved Prediction of Ovarian Cancer Surgery Recruiting

2023-503398-39-00 Phase II 1 country Aarhus University
Phase I/II Safety and Tolerability Study of striatal administration of AB-1001 in adult subjects with Early Manifest Huntington's Disease (H… Ended

2024-510895-18-00 Phase I (FiH) 1 country AskBio France
Mangafodipir - an intracellular contrast agent for Magnetic Resonance Imaging (MRI): Measuring manganese uptake rate in heart failure patien… Ended

2023-508118-40-01 Phase II 1 country IC Targets AS
[18F]-Fludarabine PET/MR Imaging for the Assessment of Newly-diagnosed Primary Central Nervous System (CNS) Lymphoma : a Pilot PET-MRI Study Ended

2024-512758-62-00 Phase I/II 1 country Assistance Publique Hopitaux De Paris
PLAQUE AND BRAIN INFLAMMATION IN SYMPTOMATIC CAROTID STENOSIS: ROLE OF THE FICOLIN-2 STATEMENT Ended

2023-504573-20-00 Phase II 1 country Hospices Civils De Lyon
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Phase II 7 countries Biogen Idec Research Limited
A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe… Ended

2022-501884-41-00 Phase III 7 countries Bayer AG
A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno… Ended

2022-501885-24-00 Phase III 8 countries Bayer AG

Showing 1–15 of 15 trials

← All drugs A–Z